<DOC>
	<DOCNO>NCT01517932</DOCNO>
	<brief_summary>Dexmedetomidine highly selective α2 adrenoreceptor agonist approve US FDA short-term postoperative sedation analgesia.It also reduce stress response without respiratory depression . In prospective , randomize , double-blind , placebo-controlled study，we give dexmedetomidine saline placebo 1h operation assessed effect dexmedetomidine stress response postoperative analgesia patient undergo thoracotomy anesthesia recovery period .</brief_summary>
	<brief_title>Effects Dexmedetomidine Stress Response Postoperative Analgesia</brief_title>
	<detailed_description>Dexmedetomidine significantly reduce emergence agitation postoperative pain patient receive chest surgery</detailed_description>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>American Society Anaesthesiologists Physical Status ( ASAPS ) I II undergo selective thoracotomy weight 45 75kg operation time 24 hour history neurologic disease history chronic analgesic intake history allergic reaction experimental durgs history renal insufficiency history hepatic dysfunction history coagulation disorder woman lactation participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>